Nutriband Inc. Reports Stable Sales with No Revenue from R&D Services; Gross Margin Declines Due to Lower Tape Sales Margins

Reuters

04-29

<a href="https://laohu8.com/S/NTRB">Nutriband Inc.</a> Reports Stable Sales with No Revenue from R&D Services; Gross Margin Declines Due to Lower Tape Sales Margins

Nutriband Inc. has released its annual report for the fiscal year ending January 31, 2025. The company reported proceeds of $8.4 million from equity financing with European investors on April 19, 2024. Management has expressed confidence in generating sufficient funds from operations to support the company's activities for the next twelve months, indicating improved business performance and the ability to continue as a going concern. In a significant business update, Nutriband's primary focus remains on the development of its AVERSA™ Abuse Deterrent Transdermal Products. The consolidated financial statements include the operations of its wholly owned subsidiaries, Nutriband Ltd., 4P Therapeutics LLC, and Pocono Pharmaceuticals Inc. The company continues to evaluate its estimates and assumptions to ensure accurate financial reporting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-036201), on April 28, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2531790264"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531790264\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2531790264?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-29 05:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531790264","market":"us","top_or_hot":-1,"title":"Nutriband Inc. Reports Stable Sales with No Revenue from R&D Services; Gross Margin Declines Due to Lower Tape Sales Margins","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NTRB\">Nutriband Inc.</a> Reports Stable Sales with No Revenue from R&amp;D Services; Gross Margin Declines Due to Lower Tape Sales Margins\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nutriband Inc. has released its annual report for the fiscal year ending January 31, 2025. The company reported proceeds of $8.4 million from equity financing with European investors on April 19, 2024. Management has expressed confidence in generating sufficient funds from operations to support the company's activities for the next twelve months, indicating improved business performance and the ability to continue as a going concern. In a significant business update, Nutriband's primary focus remains on the development of its AVERSA™ Abuse Deterrent Transdermal Products. The consolidated financial statements include the operations of its wholly owned subsidiaries, Nutriband Ltd., 4P <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> LLC, and Pocono Pharmaceuticals Inc. The company continues to evaluate its estimates and assumptions to ensure accurate financial reporting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-036201), on April 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nutriband Inc. Reports Stable Sales with No Revenue from R&D Services; Gross Margin Declines Due to Lower Tape Sales Margins</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNutriband Inc. Reports Stable Sales with No Revenue from R&D Services; Gross Margin Declines Due to Lower Tape Sales Margins\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-29 05:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NTRB\">Nutriband Inc.</a> Reports Stable Sales with No Revenue from R&amp;D Services; Gross Margin Declines Due to Lower Tape Sales Margins\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nutriband Inc. has released its annual report for the fiscal year ending January 31, 2025. The company reported proceeds of $8.4 million from equity financing with European investors on April 19, 2024. Management has expressed confidence in generating sufficient funds from operations to support the company's activities for the next twelve months, indicating improved business performance and the ability to continue as a going concern. In a significant business update, Nutriband's primary focus remains on the development of its AVERSA™ Abuse Deterrent Transdermal Products. The consolidated financial statements include the operations of its wholly owned subsidiaries, Nutriband Ltd., 4P <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> LLC, and Pocono Pharmaceuticals Inc. The company continues to evaluate its estimates and assumptions to ensure accurate financial reporting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-036201), on April 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTRB","symbol_name":"Nutriband Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nNDL3K8PXS:1","article_id":"2531790264","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531790264","pubTimestamp":1745875333,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nutriband Inc. has released its annual report for the fiscal year ending January 31, 2025. The company reported proceeds of $8.4 million from equity financing with European investors on April 19, 2024. Management has expressed confidence in generating sufficient funds from operations to support the company's activities for the next twelve months, indicating improved business performance and the ability to continue as a going concern. In a significant business update, Nutriband's primary focus remains on the development of its AVERSA Abuse Deterrent Transdermal Products. The consolidated financial statements include the operations of its wholly owned subsidiaries, Nutriband Ltd., 4P Therapeutics LLC, and Pocono Pharmaceuticals Inc. The company continues to evaluate its estimates and assumptions to ensure accurate financial reporting.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NTRB":"Nutriband Inc."},"translate_title":"Nutriband Inc.报告销售额稳定，没有研发服务收入；由于胶带销售利润率下降，毛利率下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRB":0.9},"content_text":"Nutriband Inc. Reports Stable Sales with No Revenue from R&D Services; Gross Margin Declines Due to Lower Tape Sales Margins\n    \n\n        Nutriband Inc. has released its annual report for the fiscal year ending January 31, 2025. The company reported proceeds of $8.4 million from equity financing with European investors on April 19, 2024. Management has expressed confidence in generating sufficient funds from operations to support the company's activities for the next twelve months, indicating improved business performance and the ability to continue as a going concern. In a significant business update, Nutriband's primary focus remains on the development of its AVERSA™ Abuse Deterrent Transdermal Products. The consolidated financial statements include the operations of its wholly owned subsidiaries, Nutriband Ltd., 4P Therapeutics LLC, and Pocono Pharmaceuticals Inc. The company continues to evaluate its estimates and assumptions to ensure accurate financial reporting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-036201), on April 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}